EP4728075A2 - Zusammensetzungen und verfahren zur apoe-modulierung - Google Patents

Zusammensetzungen und verfahren zur apoe-modulierung

Info

Publication number
EP4728075A2
EP4728075A2 EP24824221.6A EP24824221A EP4728075A2 EP 4728075 A2 EP4728075 A2 EP 4728075A2 EP 24824221 A EP24824221 A EP 24824221A EP 4728075 A2 EP4728075 A2 EP 4728075A2
Authority
EP
European Patent Office
Prior art keywords
nucleic acid
isolated nucleic
apoe
seq
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24824221.6A
Other languages
English (en)
French (fr)
Inventor
Asa Abeliovich
Herve Rhinn
Laura Heckman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leal Therapeutics Inc
Original Assignee
Leal Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leal Therapeutics Inc filed Critical Leal Therapeutics Inc
Publication of EP4728075A2 publication Critical patent/EP4728075A2/de
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3222'-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/341Gapmers, i.e. of the type ===---===

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP24824221.6A 2023-06-16 2024-06-14 Zusammensetzungen und verfahren zur apoe-modulierung Pending EP4728075A2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363508831P 2023-06-16 2023-06-16
US202363588136P 2023-10-05 2023-10-05
US202463556391P 2024-02-21 2024-02-21
PCT/US2024/034006 WO2024259232A2 (en) 2023-06-16 2024-06-14 Compositions and methods for modulating apoe

Publications (1)

Publication Number Publication Date
EP4728075A2 true EP4728075A2 (de) 2026-04-22

Family

ID=93852762

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24824221.6A Pending EP4728075A2 (de) 2023-06-16 2024-06-14 Zusammensetzungen und verfahren zur apoe-modulierung

Country Status (2)

Country Link
EP (1) EP4728075A2 (de)
WO (1) WO2024259232A2 (de)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021178374A2 (en) * 2020-03-05 2021-09-10 Synerk Inc. Compounds and methods for reducing apoe expression

Also Published As

Publication number Publication date
WO2024259232A3 (en) 2025-04-17
WO2024259232A2 (en) 2024-12-19

Similar Documents

Publication Publication Date Title
JP7354342B2 (ja) タウ発現を調節するための組成物
JP6924242B2 (ja) C9orf72発現を調節するための組成物
US20220411796A1 (en) Compositions and methods for decreasing tau expression
US11781135B2 (en) Methods for treating Alzheimer's disease
EP3449926B1 (de) Zusammensetzungen und verfahren zur modulation der smn2-aufspaltung im körper eines patienten
EP3061824B1 (de) Organische zusammensetzungen zur behandlung von beta-enac-bedingten erkrankungen
CN105637090A (zh) 用于调节c9orf72表达的组合物
JP2024504266A (ja) リジン分解関連障害の治療
EP4728075A2 (de) Zusammensetzungen und verfahren zur apoe-modulierung
EP4677088A2 (de) Zusammensetzungen und verfahren zur gls1-modulierung
WO2024187106A2 (en) Compositions and methods for modulating grin2a
WO2024187102A2 (en) Compositions and methods for modulating c3
AU2024231822A1 (en) Compositions and methods for modulating sptlc1
HK40108162A (en) Compositions and methods for decreasing tau expression
WO2024251725A1 (en) Oligonucleotides targeting gal3st1
JP2023554579A (ja) 核内受容体サブファミリー1グループhメンバー3(nr1h3)発現を阻害するための組成物および方法
HK40000192A (en) Compositions and methods for modulation of smn2 splicing in a subject
HK40000192B (en) Compositions and methods for modulation of smn2 splicing in a subject
HK1254822B (en) Compositions and methods for decreasing tau expression
BR112018012304B1 (pt) Oligonucleotídeo, seu uso para o tratamento de uma doença associada à tau, e composição

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251222

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR